Four cowpox virus (CPXV) outbreaks occurred in unrelated alpaca herds in Eastern Germany during 2012–2017. All incidents were initially noticed due to severe, generalized, and finally lethal CPXV infections, which were confirmed by testing of tissue and serum samples. As CPXV-infection has been described in South American camelids (SACs) only three times, all four herds were investigated to gain a deeper understanding of CPXV epidemiology in alpacas. The different herds were investigated twice, and various samples (serum, swab samples, and crusts of suspicious pox lesions, feces) were taken to identify additionally infected animals. Serum was used to detect CPXV-specific antibodies by performing an indirect immunofluorescence assay (iIFA); swab samples, crusts, and feces were used for detection of CPXV-specific DNA in a real-time PCR. In total, 28 out of 107 animals could be identified as affected by CPXV, by iIFA and/or PCR. Herd seroprevalence ranged from 16.1% to 81.2%. To investigate the potential source of infection, wild small mammals were trapped around all alpaca herds. In two herds, CPXV-specific antibodies were found in the local rodent population. In the third herd, CPXV could be isolated from a common vole (Microtus arvalis) found drowned in a water bucket used to water the alpacas. Full genome sequencing and comparison with the genome of a CPXV from an alpaca from the same herd reveal 99.997% identity, providing further evidence that the common vole is a reservoir host and infection source of CPXV. Only in the remaining fourth herd, none of the trapped rodents were found to be CPXV-infected. Rodents, as ubiquitous reservoir hosts, in combination with increasingly popular alpacas, as susceptible species, suggest an enhanced risk of future zoonotic infections.

ZusammenfassungDie Infektion mit Kuhpockenvirus (cowpox virus, CPXV) ist eine sporadisch auftretende, meldepflichtige Erkrankung mit zoonotischem Potenzial. Sie wurde in den letzten sechs Jahrzehnten sowohl bei Haustieren (Katze, Hund, Pferd, Rind) als auch bei Zootieren (z. B. Elefant, Nashorn, Okapi) in größerem Umfang beschrieben und erforscht. Dagegen finden sich in der Literatur nur drei Fallberichte über diese Infektion bei Neuweltkameliden (NWK). Ziel dieser Übersichtsarbeit war, den aktuellen Kenntnisstand zum klinischen Erscheinungsbild der CPXV-Infektion bei NWK zusammenfassend darzustellen und mit dem bei anderen Tierarten zu vergleichen. Auch bei Alpaka und Lama erfolgt die Übertragung des Virus bei direktem Tierkontakt oder durch orale Virusaufnahme, wobei Mikroläsionen der Haut oder Schleimhaut als Eintrittspforten für das Virus fungieren. Klinisch kann ein lokal begrenzter, milder Verlauf mit Pusteln oder Krusten der Haut, die auf einzelne Körperbereiche (Kopf, Hals, Gliedmaßen, Perinealbereich) beschränkt bleiben, beobachtet werden. Dem gegenüber steht ein generalisierter, meist letaler Infektionsverlauf mit multifokal bis diffus verteilten Hautläsionen (Papeln, Pusteln, Krusten, ulzerierende Wunden) und Virusreplikation in weiteren Organen. Die Tiere entwickeln unter anderem Konjunktivitis, Stomatitis und Rhinitis gepaart mit unspezifischen Symptomen wie Inappetenz, Apathie und Fieber. Die klinische Manifestation scheint wie bei anderen Pockenvirusinfektionen durch Faktoren, die das Immunsystem schwächen, begünstigt zu werden. Bisher gibt es keinen Hinweis auf NWK-spezifische Besonderheiten in Bezug auf das klinische Erscheinungsbild der CPXV-Infektion. In Hinblick auf das Verständnis der Pathogenese und Epidemiologie dieser Erkrankung, speziell bei NWK, eröffnet sich Raum für weitere Forschung.

In Europe, cowpox virus (CPXV) infection in South American camelids occurs as a so-called spill-over infection. Although infected animals generally have a mild form of the disease and survive, cases of fatal generalised CPXV infection have also been described. Prevention by prophylactic vaccination is the only way to protect animals from disease. In the present study, modified vaccinia virus Ankara (MVA) vaccine, which has been successfully used in many animal species, was used in a prime-boost vaccination regimen in two alpaca herds with a history of CPXV infection. The focus of the study was the prevention of further clinical cases, and to determine the safety and immunogenicity of the MVA vaccine in alpacas. The MVA vaccine was well tolerated and safe in the 94 animals vaccinated. An indirect immunofluorescence assay (IFA) using MVA as an antigen showed that the seroprevalence of antibody after booster vaccination was 81.3% in herd I and 91.7% in herd II. Detectable antibody titres declined to 15.6% in herd I and 45.8% in herd II over a 12-month period after booster vaccination. Animals could be divided into four groups based on individual antibody titres determined over one year: Group 1 consisted of 19.3% of animals that were seropositive until the end of the trial period; Group 2 consisted of 58.0% of animals that were seropositive after booster vaccination, but seronegative one year later; Group 3 consisted of 14.7% of animals that were not seropositive at any time point; and Group 4 consisted of 7.9% of animals that were seropositive after initial immunisation, seronegative six months later, but seropositive or intermediate in IFA one year after immunisation, likely because of natural exposure. In new-born crias born to MVA-vaccinated mares, specific maternal antibodies were detected in 50.0% of animals up to 14 weeks of age. Our results confirm that MVA vaccination is a feasible tool for the prevention of CPXV disease in alpacas. Long-term studies are needed to verify future vaccination regimen in CPXV affected herds.